title: [Pilot study of intermittent administration of liposomal amphotericin B for chronic pulmonary aspergillosis].
abstract: Treatment for chronic pulmonary aspergillosis is difficult and frequently is required for prolong period. In outpatients setting, only voriconazole and itraconazole could be used. Since liposomal amphotericin B (L-AMB) demonstrated prolonged half-time, we have investigated the feasibility of L-AMB in outpatient setting. Three cases of chronic pulmonary aspergillosis were treated with intermittent administration of 2.5 mg/kg of L-AMB twice weekly for one month in outpatient settings. Improve of symptoms was attained in 2 of 3 cases. Improvement of chest images were in 2 of 3, improvement of laboratory test were in 2 of 3. Adverse events were only fatigue and short period of fever. No recurrence of pulmonary aspergillosis has been found after treatment. Intermittent administration of L-AMB in outpatient settings could be an option for pulmonary aspergillosis.
authors.forename: Masaki
authors.initials: M
authors.lastname: Fujita
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Hirano
authors.forename: Takemasa
authors.initials: T
authors.lastname: Matsumoto
authors.forename: Kentaro
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000368:Aged; D000666:Amphotericin B / Q000008:administration & dosage* / Q000009:adverse effects; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D010865:Pilot Projects; D055732:Pulmonary Aspergillosis / Q000188:drug therapy*
chemical_list: D000935:Antifungal Agents; C068538:liposomal amphotericin B; D000666:Amphotericin B